Apricus Biosciences Company Review & Valuation

APRI
Nasdaq
Latest Price
0.22USD

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology.

The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.

It has a license and stock issuance agreement with Forendo Pharma Ltd.

to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men.

Apricus Biosciences, Inc.

operates in Europe, Canada, Latin America, and the Asia Pacific.

The company was formerly known as NexMed, Inc.

and changed its name to Apricus Biosciences, Inc.

in September 2010.

Apricus Biosciences, Inc.

was founded in 1987 and is headquartered in San Diego, California.

Industry
Biotechnology
HQ Location
San Diego, California

Stock Price

Price data not available for Apricus Biosciences.

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl